Table 1.
Patients demographics in the pre-operative period.
| All patients | 50–50 criterion | ISGLS definition | |||
| PHLF | No PHLF | PHLF | No PHLF | ||
| Surgical indication, n (%) | |||||
| – All | 597 (100%) | 3 (0.8%) | 382 (99.2%) | 43 (11.2%) | 342 (88.8%) |
| – HCC | 95 (15.9%) | 0 (0%) | 68 (100%) | 6 (8.8%) | 62 (91.2%) |
| – CRM | 236 (39.5%) | 0 (0%) | 158 (100%) | 17 (10.8%) | 141 (89.2%) |
| – Others | 266 (44.6%) | 3 (1.9%) | 156 (98.1%) | 20 (12.6%) | 139 (87.4%) |
| Platelet count (G/l), median+/−SD | 212+/−85.3 | 226.5+/−2.12 | 211+/−84.3 | 211+/−89.7 | 211+/−83.5 |
| Platelets <100G/l, n (%) | 24 (5.3%)∗ | 0 (0%)† | 17 (100%)† | 1 (5.9%)† | 16 (94.1%)† |
| Platelets <150G/l, n (%) | 80 (17.8%)∗ | 0 (0%)† | 55 (100%)† | 5 (9.1%)† | 50 (90.9%)† |
| Anti-platelet drug (yes), n (%) | 35 (5.9%)∗ | 0 (0%)† | 28 (100%)† | 4 (14.3%)† | 24 (85.7%)† |
∗
Proportion reported to the total number of patients.
†
Proportion reported to the number of patients with a positive outcome (thrombocytopenia or anti-platelet drug). Some values are missing.
Median+/−SD or number (proportion) are reported. CRM = colorectal cancer metastasis, HCC = hepatocellular carcinoma, PHLF = post-hepatectomy lifer failure.